Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer

Phase I Feasibility and Safety Study of Nivolumab in Combination With Irinotecan in Relapsed or Refractory Small Cell Lung Cancer (SCLC) Followed by Maintenance Nivolumab

This study will determine the frequency of adverse events (side effects) in patients with relapsed or refractory small cell lung cancer (SCLC) when given nivolumab and irinotecan together followed by nivolumab maintenance. This study will test the safety of the study treatments when given together and see what effect (good or bad) it has on participants and their cancer.

Inclusion Criteria:

• Confirmed SCLC with known UGT1A genotype.
• Patients who have received at least 1 prior platinum-based chemotherapy.
• Life expectancy of 3 months or more.
• Measurable disease.

Exclusion Criteria:

• Patients with UGT1A polymorphism.
• Currently receiving chemotherapy.
• Pregnant and nursing women.